Serum endocan level and diastolic functions in the case of lead exposure

Background/aim: Lead can cause morphological and functional changes in heart, and inflammation and endothelial dysfunction invasculature. Endocan, as a novel indicator of endothelial dysfunction, has been used for cardiovascular diseases. This study investigatedthe relationship between lead exposure, endocan levels, and diastolic functions.Materials and methods: A total of 51 lead-exposed workers without a known cardiovascular disease or risk factors and 54 healthycontrols were enrolled. All participants underwent transthoracic echocardiography. Blood lead and serum endocan levels were analyzed.Results: Baseline demographic and clinical characteristics were found to be similar between groups. Median blood lead (32 vs 1.5 µg/dL,P < 0.001) and serum endocan levels (67 vs 57.1 pg/mL, P = 0.02) were significantly higher in the lead-exposed group. Serum endocanlevel showed a positive correlation with blood lead levels (r = 0.404, P = 0.003) in lead-exposed workers. Serum endocan level was anindependent risk factor for increased E/E’ ratio (β = 0.704, P = 0.002) and left atrial volume index (β = 1.158, P = 0.011) and higher levelof lead in blood was an independent risk factor for increased E wave (β = 8.004, P = 0.022) in lead-exposed workers.Conclusion: Worsened diastolic functions may be seen in the course of lead exposure. Due to sharing a similar mechanism, a higherserum level of endocan may be a valuable laboratory clue for impaired diastolic function in this population.

Anahtar Kelime:

Konular: Cerrahi

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık

1. Jain NB, Potula V, Schwartz J, Vokonas PS, Sparrow D, Wright RO, Nie H, Hu H. Lead levels and ischemic heart disease in a prospective study of middle-aged and elderly men: the VA Normative Aging Study. Environ Health Perspect 2007; 115: 871-875.
2. Gambelunghe A, Sallsten G, Borne Y, Forsgard N, Hedblad B, Nilsson P, Fagerberg B, Engstrom G, Barregard L. Lowlevel exposure to lead, blood pressure, and hypertension in a population-based cohort. Environ Res 2016; 149: 157-163.
3. Poreba R, Gac P, Poreba M, Mazur G. Echocardiographic assessment of myocardial function in workers occupationally exposed to lead without clinically evident heart disease. Environ Toxicol Pharmacol 2013; 36: 522-528.
4. Vaziri ND. Mechanisms of lead-induced hypertension and cardiovascular disease. Am J Physiol Heart Circ Physiol 2008; 295: 454-465.
5. Sarrazin S, Adam E, Lyon M, Depontieu F, Motte V, Landolfi C, Lortat-Jacob H, Bechard D, Lassalle P, Delehedde M. Endocan or endothelial cell specific molecule-1 (ESM-1): a potential novel endothelial cell marker and a new target for cancer therapy. Biochim Biophys Acta 2006; 1765: 25-37.
6. Aparci M, Isilak Z, Uz O, Yalcin M, Kucuk U. Endocan and endothelial dysfunction. Angiology 2015; 66: 488-489.
7. Wang XS, Yang W, Luo T, Wang JM, Jing YY. Serum endocan levels are correlated with the presence and severity of coronary artery disease in patients with hypertension. Genet Test Mol Biomarkers 2015; 19:124-127.
8. Balta S, Demirkol S, Ozturk C, Yildirim AO, Demir M, Celik T. The relation between endocan levels and subclinic atherosclerosis. Clin Appl Thromb Hemost 2016; 22: 495-496.
9. Kundi H, Balun A, Cicekcioglu H, Karayigit O, Topcuoglu C, Kilinckaya MF, Kiziltunc E, Cetin M, Ornek E. Admission endocan level may be a useful predictor for in-hospital mortality and coronary severity index in patients with STsegment elevation myocardial infarction. Angiology 2017; 68: 46-51.
10. Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, Picard MH, Roman MJ, Seward J, Shanewise JS et al. Recommendations for chamber quantification: a report from the American Society of Echocardiography’s Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr 2005; 18: 1440- 1463.
11. Ozaki K, Toshikuni N, George J, Minato T, Matsue Y, Arisawa T, Tsutsumi M. Serum endocan as a novel prognostic biomarker in patients with hepatocellular carcinoma. J Cancer 2014; 5: 221-230.
12. Menke A, Muntner P, Batuman V, Silbergeld EK, Guallar E. Blood lead below 0.48 micromol/L (10 microg/dL) and mortality among US adults. Circulation 2006; 114: 1388-1394.
13. Ma LN, Zhao SP, Gao M, Zhou QC, Fan P. Endothelial dysfunction associated with left ventricular diastolic dysfunction in patients with coronary heart disease. Int J Cardiol 2000; 72:275-279.
14. Sirivarasai J, Wananukul W, Kaojarern S, Chanprasertyothin S, Thongmung N, Ratanachaiwong W, Sura T, Sritara P. Association between inflammatory marker, environmental lead exposure, and glutathione S-transferase gene. Biomed Res Int 2013; 2013: 474963.
15. Vaziri ND, Khan M. Interplay of reactive oxygen species and nitric oxide in the pathogenesis of experimental lead-induced hypertension. Clin Exper Pharmacol Physiol 2007; 34: 920- 925.
16. Paulus WJ, Vantrimpont PJ, Shah AM. Paracrine coronary endothelial control of left ventricular function in humans. Circulation 1995; 92: 2119-2126.
17. Elesber AA, Redfield MM, Rihal CS, Prasad A, Lavi S, Lennon R, Mathew V, Lerman LO, Lerman A. Coronary endothelial dysfunction and hyperlipidemia are independently associated with diastolic dysfunction in humans. Am Heart J 2007; 153: 1081-1087.
18. Munzel T, Gori T, Keaney JF Jr., Maack C, Daiber A. Pathophysiological role of oxidative stress in systolic and diastolic heart failure and its therapeutic implications. Eur Heart J 2015; 36: 2555-2564.
19. Peller M, Ozieranski K, Balsam P, Grabowski M, Filipiak KJ, Opolski G. Influence of beta-blockers on endothelial function: A meta-analysis of randomized controlled trials. Cardiol J 2015; 22:708-716.
20. Iavicoli I, Carelli G, Stanek EJ 3rd, Castellino N, Calabrese EJ. Below background levels of blood lead impact cytokine levels in male and female mice. Toxicol Appl Pharmacol 2006; 210: 94-99.
21. Balta S, Mikhailidis DP, Demirkol S, Ozturk C, Kurtoglu E, Demir M, Celik T, Turker T, Iyisoy A. Endocan—a novel inflammatory indicator in newly diagnosed patients with hypertension: a pilot study. Angiology 2014; 65: 773-777.
22. Cimen T, Efe TH, Akyel A, Sunman H, Algul E, Sahan HF, Erden G, Ozdemir S, Alay EF, Dogan M et al. Human endothelial cell-specific molecule-1 (endocan) and coronary artery disease and microvascular angina. Angiology 2016; 67: 846-853.
23. Kose M, Emet S, Akpinar TS, Kocaaga M, Cakmak R, Akarsu M, Yuruyen G, Arman Y, Tukek T. Serum Endocan Level and the Severity of Coronary Artery Disease: A Pilot Study. Angiology 2015; 66: 727-731.
24. Arman Y, Akpinar TS, Kose M, Emet S, Yuruyen G, Akarsu M, Ozcan M, Yegit O, Cakmak R, Altun O et al. Effect of glycemic regulation on endocan levels in patients with diabetes: a preliminary study. Angiology 2016; 67:239-244.
25. Qiu CR, Fu Q, Sui J, Zhang Q, Wei P, Wu Y, Zhu K, Lu Y, Wan P. Analysis of serum endothelial cell-specific molecule 1 (endocan) level in type 2 diabetes mellitus with acute stsegment elevation myocardial infarction and its correlation: a pilot study. Angiology 2017; 68: 74-78.
26. Vaziri ND, Liang K, Ding Y. Increased nitric oxide inactivation by reactive oxygen species in lead-induced hypertension. Kidney Int 1999; 56: 1492-1498.
27. Balta S, Mikhailidis DP, Demirkol S, Ozturk C, Celik T, Iyisoy A. Endocan: a novel inflammatory indicator in cardiovascular disease? Atherosclerosis 2015; 243: 339-343.

APA	Kara H, KARAKULAK U, Gunduzoz M, bal c, Alisik M, BÜYÜKŞEKERCİ M, IRİTAS S, Yılmaz Ö, TUTKUN L (2019). Serum endocan level and diastolic functions in the case of lead exposure. , 66 - 73. 10.3906/sag-1801-146
Chicago	Kara Halil,KARAKULAK Uğur Nadir,Gunduzoz Meside,bal ceylan,Alisik Murat,BÜYÜKŞEKERCİ MURAT,IRİTAS Servet Birgin,Yılmaz Ömer Hinç,TUTKUN Lütfiye Serum endocan level and diastolic functions in the case of lead exposure. (2019): 66 - 73. 10.3906/sag-1801-146
MLA	Kara Halil,KARAKULAK Uğur Nadir,Gunduzoz Meside,bal ceylan,Alisik Murat,BÜYÜKŞEKERCİ MURAT,IRİTAS Servet Birgin,Yılmaz Ömer Hinç,TUTKUN Lütfiye Serum endocan level and diastolic functions in the case of lead exposure. , 2019, ss.66 - 73. 10.3906/sag-1801-146
AMA	Kara H,KARAKULAK U,Gunduzoz M,bal c,Alisik M,BÜYÜKŞEKERCİ M,IRİTAS S,Yılmaz Ö,TUTKUN L Serum endocan level and diastolic functions in the case of lead exposure. . 2019; 66 - 73. 10.3906/sag-1801-146
Vancouver	Kara H,KARAKULAK U,Gunduzoz M,bal c,Alisik M,BÜYÜKŞEKERCİ M,IRİTAS S,Yılmaz Ö,TUTKUN L Serum endocan level and diastolic functions in the case of lead exposure. . 2019; 66 - 73. 10.3906/sag-1801-146
IEEE	Kara H,KARAKULAK U,Gunduzoz M,bal c,Alisik M,BÜYÜKŞEKERCİ M,IRİTAS S,Yılmaz Ö,TUTKUN L "Serum endocan level and diastolic functions in the case of lead exposure." , ss.66 - 73, 2019. 10.3906/sag-1801-146
ISNAD	Kara, Halil vd. "Serum endocan level and diastolic functions in the case of lead exposure". (2019), 66-73. https://doi.org/10.3906/sag-1801-146

APA	Kara H, KARAKULAK U, Gunduzoz M, bal c, Alisik M, BÜYÜKŞEKERCİ M, IRİTAS S, Yılmaz Ö, TUTKUN L (2019). Serum endocan level and diastolic functions in the case of lead exposure. Turkish Journal of Medical Sciences, 49(1), 66 - 73. 10.3906/sag-1801-146
Chicago	Kara Halil,KARAKULAK Uğur Nadir,Gunduzoz Meside,bal ceylan,Alisik Murat,BÜYÜKŞEKERCİ MURAT,IRİTAS Servet Birgin,Yılmaz Ömer Hinç,TUTKUN Lütfiye Serum endocan level and diastolic functions in the case of lead exposure. Turkish Journal of Medical Sciences 49, no.1 (2019): 66 - 73. 10.3906/sag-1801-146
MLA	Kara Halil,KARAKULAK Uğur Nadir,Gunduzoz Meside,bal ceylan,Alisik Murat,BÜYÜKŞEKERCİ MURAT,IRİTAS Servet Birgin,Yılmaz Ömer Hinç,TUTKUN Lütfiye Serum endocan level and diastolic functions in the case of lead exposure. Turkish Journal of Medical Sciences, vol.49, no.1, 2019, ss.66 - 73. 10.3906/sag-1801-146
AMA	Kara H,KARAKULAK U,Gunduzoz M,bal c,Alisik M,BÜYÜKŞEKERCİ M,IRİTAS S,Yılmaz Ö,TUTKUN L Serum endocan level and diastolic functions in the case of lead exposure. Turkish Journal of Medical Sciences. 2019; 49(1): 66 - 73. 10.3906/sag-1801-146
Vancouver	Kara H,KARAKULAK U,Gunduzoz M,bal c,Alisik M,BÜYÜKŞEKERCİ M,IRİTAS S,Yılmaz Ö,TUTKUN L Serum endocan level and diastolic functions in the case of lead exposure. Turkish Journal of Medical Sciences. 2019; 49(1): 66 - 73. 10.3906/sag-1801-146
IEEE	Kara H,KARAKULAK U,Gunduzoz M,bal c,Alisik M,BÜYÜKŞEKERCİ M,IRİTAS S,Yılmaz Ö,TUTKUN L "Serum endocan level and diastolic functions in the case of lead exposure." Turkish Journal of Medical Sciences, 49, ss.66 - 73, 2019. 10.3906/sag-1801-146
ISNAD	Kara, Halil vd. "Serum endocan level and diastolic functions in the case of lead exposure". Turkish Journal of Medical Sciences 49/1 (2019), 66-73. https://doi.org/10.3906/sag-1801-146